Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | NR3C1 | P04150 | 6/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.38 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.38 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.38 |
| ▸ | ESRRA | P11474 | 1/20 | 0.36 |
| ▸ | PLG | P00747 | 1/20 | 0.36 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
| ▸ | PLAT | P00750 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2111495 | 0.82 | PTGDR2 (0.51) | FFAR1NR3C1PTGDR2NCEH1TBXA2R | |
| SCHEMBL1369521 | 0.82 | PTGDR2 (0.38) | FFAR1PTGDR2TBXA2RPLGPLAU | |
| SCHEMBL1368738 | 0.80 | TDP1 (0.44) | CYP1A2CYP2C19PPARA | |
| SCHEMBL1371347 | 0.79 | PKM (0.50) | FFAR1ARPLGPLAUPLAT | |
| SCHEMBL1369990 | 0.79 | PPARA (0.54) | PTGDR2CYP1A2CYP2C19PPARA | |
| SCHEMBL6001992 | 0.79 | AKR1C3 (0.42) | CYP1A2CYP2C19 | |
| SCHEMBL1367990 | 0.78 | PTGDR2 (0.38) | FFAR1NR3C1PTGDR2PLGPLAU | |
| SCHEMBL22769041 | 0.77 | GAA (0.44) | NR3C1PLGPLAUPLATPPARA | |
| SCHEMBL1371128 | 0.77 | PTPN1 (0.43) | PLGPLAUPLATCYP1A2CYP2C19 | |
| SCHEMBL1369029 | 0.77 | ABCB11 (0.41) | FFAR1PTGDR2ESRRACYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273769-B2 | Phenoxy acetic acid derivatives | MERCK SERONO SA (CH) | 2012-09-25 | — | — | US | disclosed |
| US-20110288066-A1 | PHENOXY ACETIC ACID DERIVATIVES | MERCK SERONO S.A. (CH) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288066-A1 | PHENOXY ACETIC ACID DERIVATIVES | HRH2, HRH1, HRH3 | FFAR1 55/4885NR3C1 26/4885AR 743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.